The cancer cell line under this study (NIH-OVCAR3) is well characterized as a high-grade ovarian serous carcinoma cell line with a missense mutation in the TP53 gene (R248Q) [60] and an appropriate model system to study drug resistance in ovarian cancer. This evidence concerns the gene TP53 and ovarian carcinoma.